Table of Contents
Welcome and Methods
- Introduction
- Methods
- Methods: Table 1 - Summary of the Process and Methods for the Guidance Development
- Methods: Table 2 - Rating System Used to Rate the Level of the Evidence and Strength of the Recommendation for Each Recommendation
- Methods: Table 3 - Commonly Used Abbreviations and Their Expansions
Evaluate, Test, Monitor
- Testing, Evaluation, and Monitoring of Hepatitis C
- HCV Testing and Linkage to Care
- Testing and Linkage to Care: Table 1 - FDA-approved, Commercially Available Anti-HCV Screening Assays
- Testing and Linkage to Care: Table 2 - Measures to Prevent Transmission of HCV
- Testing and Linkage to Care: Table 3 - Common Barriers to HCV Treatment and Potential Strategies
- Testing and Linkage to Care: Figure 1 - CDC Recommended Testing Sequence for Identifying Current HCV Infection
- When and in Whom to Initiate HCV Therapy
- Overview of Cost, Reimbursement, and Cost-effectiveness Considerations for Hepatitis C Treatment Regimens
- Monitoring Patients Who Are Starting HCV Treatment, Are on Treatment, or Have Completed Therapy
- Not Recommended Regimens In HCV Treatment
Treatment-naive
- Initial Treatment of HCV Infection
- Treatment-naive Genotype 1
- Treatment-naive Genotype 1a Without Cirrhosis
- Treatment-naive Genotype 1a with Compensated Cirrhosis
- Treatment-naive Genotype 1b Without Cirrhosis
- Treatment-naive Genotype 1b with Compensated Cirrhosis
- Treatment-naive Genotype 2
- Treatment-naive Genotype 2 Without Cirrhosis
- Treatment-naive Genotype 2 with Compensated Cirrhosis
- Treatment-naive Genotype 3
- Treatment-naive Genotype 3 Without Cirrhosis
- Treatment-naive Genotype 3 with Compensated Cirrhosis
- Treatment-naive Genotype 4
- Treatment-naive Genotype 4 Without Cirrhosis
- Treatment-naive Genotype 4 with Compensated Cirrhosis
- Treatment-naive Genotype 5 or 6
Treatment-experienced
- Retreatment of Persons in Whom Prior Therapy Has Failed
- Treatment-experienced Genotype 1
- PEG-IFN/Ribavirin Experienced, Genotype 1a Patients Without Cirrhosis
- PEG-IFN/Ribavirin Experienced, Genotype 1a Patients with Compensated Cirrhosis
- PEG-IFN/Ribavirin Experienced, Genotype 1b Patients Without Cirrhosis
- PEG-IFN/Ribavirin Experienced, Genotype 1b Patients with Compensated Cirrhosis
- NS3 PI + Peg-IFN/Ribavirin Experienced, Genotype 1 Patients Without Cirrhosis
- NS3 PI + Peg-IFN/Ribavirin Experienced, Genotype 1 Patients with Compensated Cirrhosis
- NS5A Experienced Genotype 1 Patients
- Simeprevir Plus Sofosbuvir Experienced, Genotype 1 Patients
- Sofosbuvir plus Ribavirin, with or Without PEG-IFN, Experienced Genotype 1 Patients with or Without Cirrhosis
- Treatment-experienced Genotype 2
- PEG-IFN/Ribavirin Treatment-experienced, Genotype 2 Patients Without Cirrhosis
- PEG-IFN/Ribavirin Treatment-experienced, Genotype 2 Patients with Compensated Cirrhosis
- Sofosbuvir Plus Ribavirin Treatment-experienced, Genotype 2 Patients
- Treatment-experienced Genotype 3
- PEG-IFN/Ribavirin Experienced, Genotype 3 Patients Without Cirrhosis
- PEG-IFN/Ribavirin Experienced, Genotype 3 Patients with Compensated Cirrhosis
- Sofosbuvir Experienced, Genotype 3 Patients
- Treatment-experienced Genotype 4
- PEG-IFN/Ribavirin Experienced, Genotype 4 Patients Without Cirrhosis
- PEG-IFN/Ribavirin Experienced, Genotype 4 Patients with Compensated Cirrhosis
- Treatment-experienced Genotype 5 or 6
Unique Populations
- Management of Unique Populations with HCV Infection
- Unique Patient Populations: Patients with HIV/HCV Coinfection
- Unique Populations: Patients with Decompensated Cirrhosis
- Unique Patient Populations: Patients Who Develop Recurrent HCV Infection Post-Liver Transplantation
- Unique Patient Populations: Patients with Renal Impairment
- Management of Acute HCV Infection
- Acute Figure. Testing Algorithm for Discrete Recognized Hepatitis C Virus (HCV) Exposure